The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.
BACKGROUND
The macrolide antibiotics clarithromycin and erythromycin may potentiate calcium-channel blockers by inhibiting cytochrome P450 isoenzyme 3A4. However, this potential drug interaction is widely underappreciated and its clinical consequences have not been well characterized. We explored the risk of hypotension or shock requiring hospital admission following the simultaneous use of calcium-channel blockers and macrolide antibiotics.


METHODS
We conducted a population-based, nested, case-crossover study involving people aged 66 years and older who had been prescribed a calcium-channel blocker between Apr. 1, 1994, and Mar. 31, 2009. Of these patients, we included those who had been admitted to hospital for the treatment of hypotension or shock. For each antibiotic, we estimated the risk of hypotension or shock associated with the use of a calcium blocker using a pair-matched analytic approach to contrast each patient's exposure to each macrolide antibiotic (erythromycin, clarithromycin or azithromycin) in a seven-day risk interval immediately before admission to hospital and in a seven-day control interval one month earlier.


RESULTS
Of the 7100 patients admitted to hospital because of hypotension while receiving a calcium-channel blocker, 176 had been prescribed a macrolide antibiotic during either the risk or control intervals. Erythromycin (the strongest inhibitor of cytochrome P450 3A4) was most strongly associated with hypotension (odds ratio [OR] 5.8, 95% confidence interval [CI] 2.3-15.0), followed by clarithromycin (OR 3.7, 95% CI 2.3-6.1). Azithromycin, which does not inhibit cytochrome P450 3A4, was not associated with an increased risk of hypotension (OR 1.5, 95% CI 0.8-2.8). We found similar results in a stratified analysis of patients who received only dihydropyridine calcium-channel blockers.


CONCLUSIONS
In older patients receiving a calcium-channel blocker, use of erythromycin or clarithromycin was associated with an increased risk of hypotension or shock requiring admission to hospital. Preferential use of azithromycin should be considered when a macrolide antibiotic is required for patients already receiving a calcium-channel blocker.
Department of Medicine, University of Toronto, Ont., Canada.
Alissa J
AJ
Wright
Tara
T
Gomes
Muhammad M
MM
Mamdani
John R
JR
Horn
David N
DN
Juurlink
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017963:Azithromycin / Q000008:administration & dosage / Q000009:adverse effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects*; D016022:Case-Control Studies; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects; D018592:Cross-Over Studies; D065607:Cytochrome P-450 Enzyme Inhibitors; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D018942:Macrolides / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D016555:Matched-Pair Analysis; D009864:Ontario; D010343:Patient Admission / Q000706:statistics & numerical data
D000900:Anti-Bacterial Agents; D002121:Calcium Channel Blockers; D065607:Cytochrome P-450 Enzyme Inhibitors; D018942:Macrolides; D004917:Erythromycin; D017963:Azithromycin; D017291:Clarithromycin
Ann Pharmacother. 2001 Nov;35(11):1396-9
11724091
Ann Pharmacother. 2000 Apr;34(4):495-513
10772438
N Engl J Med. 2004 Aug 5;351(6):543-51
15295047
Clin Pharmacokinet. 1992 Aug;23(2):106-31
1511528
Ann Pharmacother. 2005 Mar;39(3):538-42
15703161
Food Chem Toxicol. 2003 Feb;41(2):201-24
12480298
Clin Pharmacol Ther. 1996 Jul;60(1):25-33
8689808
Clin Pharmacokinet. 1998 Jun;34(6):457-82
9646008
JAMA. 2003 Apr 2;289(13):1652-8
12672733
Ann Pharmacother. 1998 Mar;32(3):387-8
9533073
Br J Clin Pharmacol. 2000 Oct;50(4):285-95
11012550
Am J Epidemiol. 1991 Jan 15;133(2):144-53
1985444
DICP. 1991 Sep;25(9):1007-8
1949959
Am J Health Syst Pharm. 1998 Nov 15;55(22):2417-8
9825040
CMAJ. 2009 Mar 31;180(7):713-8
19176635
Am J Hypertens. 2006 Jul;19(7):768-73
16814135
Clin Pharmacokinet. 2000 Jan;38(1):41-57
10668858
Ther Clin Risk Manag. 2005 Mar;1(1):3-13
18360537
N Engl J Med. 2006 Mar 30;354(13):1352-61
16510739